

***The GOG Highlight Reel:
An Education Series Highlighting Newsworthy Distillation
and Emerging Global Therapies in Clinical Trials***

**July 26, 2025
Washington, DC**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "**ineligible company**" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<i>Planning Disclosures</i>				
Herzog, Thomas, MD	Planner/ Moderator		Astra Zeneca; Caris; Clovis; Eisai; Epsilogen; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics	Scientific Advisory Boards
Monk, Bradley, MD	Planner/ Moderator		Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks	Consultant (Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks) Speaker (AstraZeneca; Eisai; GSK; Immunogen; Abbvie; Merck)
<i>Speaker Disclosures</i>				
Coleman, Robert, MD	Speaker		Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Abbvie; Immunogen, Abbvie; Merck; Novartis; Valero/Valbio;	Consultant (Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Seagen/Genmab/Pfizer) Grant Contract (Genentech USA Inc; Abbvie; Immunogen, Abbvie; Merck;

FACULTY DISCLOSURE INFORMATION

			Seagen/Genmab/Pfizer; VBL; Eisai; GOG-Partners; Karyopharm	Novartis; Valero/Valbio; Seagen/Genmab/Pfizer; Karyopharm) Data & Safety Monitoring (VBL; Eisai; GOG-Partners)
Duska, Linda, MD, MPH	Speaker		Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp	Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp
Eskander, Ramez, MD	Speaker		AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana; Nuvectis Pharma, Merck, Loxo @ Lilly, Genmab/Seagen, Clovis Oncology, Acrivon therapeutics, Zentalis, Eisai, Gilead, Roche	Consultant (AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sankyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana) Research Funding (Nuvectis Pharma, GSK, Merck, Daiichi Sankyo, Loxo @ Lilly, AstraZeneca, Genmab/Seagen, Clovis Oncology, Acrivon Therapeutics, Zentalis, Eisai, Gilead, Roche)
Moore, Kathleen, MD	Speaker		Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE	Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) Travel, Accommodations, Expenses (BioNTech SE)
Olawaiye, Alexander, MD	Speaker		AstraZeneca; GSK; Merck; Daiichi Sankyo	Advisory Board
O'Malley, David, MD	Speaker		AbbVie; AdaptImmune; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; Bristol Myers Squibb; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Deciphera Pharma; Duality Bio; Eisai; Elevar; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La	Institution Received Funds for research (AbbVie; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeiGene USA, Inc.; Boston; Biomedical; Bristol Myers Squibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Incyte Corporation; IOVANCE Biotherapeutics; Karyopharm; Leap

FACULTY DISCLOSURE INFORMATION

			Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Incyte Corporation; IOVANCE Pharmaceuticals; Jazz Pharmaceuticals; Karyopharm; Laekna; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Onconova; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; SWOG; ; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis	Therapeutics, Inc.; Ludwig Institute for Ca; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics (SeaGen); Sutro Biopharma; SWOG; Verastem, Inc) Ad Board/Consultant (AbbVie; AdaptImmune; Agenus, Inc; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Jazz Pharmaceuticals; Laekna; Leap Therapeutics, Inc.; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova; Regeneron Pharmaceuticals, Inc; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis
Pothuri, Bhavana, MD, MS	Speaker		AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; Eisai; GlaxoSmithKline; GOG foundation; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries	Consultant (AstraZeneca; Eisai; GlaxoSmithKline; GOG foundation; Merck; Mersana; Seagen Inc.; Sutro) Grant/Contract (AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; GlaxoSmithKline; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries)
Randall, Leslie, MD	Speaker		AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; AbbVie; GOG Foundation	Consultant (AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; AbbVie; GOG Foundation) Research Funding (Merck; AbbVie; GOG Foundation)
Slomovitz, Brian, MD	Speaker		Seagen, Novocure; AstraZeneca; Aadi; Regeneron; Immunocore; Merck; Gilead, Eisai; Incyte	Consultant
Holley Engbert	Staff	X		
Heather Rush	Staff	X		
Kara Shumaker	Reviewer/Staff	X		
Michelle N Small, MPH	Reviewer/Staff	X		
Angeles Alvarez Secord, MD	Reviewer/Edu-Chair		AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ;	Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses

FACULTY DISCLOSURE INFORMATION

			GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Bio	Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio) Stock (Amgen; Johnson&Johnson)
Linda Duska, MD	Reviewer/Edu-Co-Chair		Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp	Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp
Stephanie Blank, MD	Reviewer		AstraZeneca; Merck; Zentalis; Acrivon; Seattle Genetics; GSK	Research Funding to Institution
David Mutch, MD	Reviewer	X		
Susan Zweizig, MD	Reviewer	X		